Sepsis can progress very quickly – patients who are not identified and treated in a timely manner risk life-threatening complications and even death. The National Institute for Health and Care Excellence (NICE) has launched a new draft quality standard on sepsis emphasising that people with life-threatening sepsis symptoms should be treated within one hour.
NICE are asking for views on the draft quality standard: https://www.nice.org.uk/guidance/indevelopment/gid-qs10032. It is out for public consultation until Friday 7 April 2017.
Early diagnosis of sepsis and therapeutic intervention are critical for facilitating effective treatment. NICE has emphasised the importance of early treatment of high-risk patients. Once the sepsis treatment is initiated, it is equally important to identify the causative organism in order to implement the appropriate therapy as quickly as possible. QuickFISH™ technology provides rapid and accurate identification of bacteria and yeast 1-3 days earlier than conventional ID methods allowing for the identification of bacteria and yeast directly from positive blood cultures in only 20 minutes.
The QuickFISH rapid molecular diagnostic assays are currently available in the following kits:
- QFSTABC1-50, Staphylococcus QuickFISH to differentiate Staphylococcus aureus from Coagulase Negative Staphylococci (CoNS)
- QFENTBC1-25, Enterococcus QuickFISH to differentiate E. faecalis from E. faecium and other enterococci
- QFGNRBC1-25, Gram-Negative QuickFISH to differentiate Pseudomonas aeruginosa from Escherichia coli and Klebsiella pneumoniae
- QFCANBC1-25, Candida QuickFISH to differentiate between C. albicans, C. glabrata and C. parapsilosis